Skip to main content
Clinical Trials/ISRCTN14585543
ISRCTN14585543
Active, not recruiting
未知

Feasibility and acceptability of a primary care liver fibrosis testing pathway centred on the diabetes annual review

Queen Mary University of London0 sites5,300 target enrollmentApril 27, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Queen Mary University of London
Enrollment
5300
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

2023 Protocol article in https://pubmed.ncbi.nlm.nih.gov/37208139/ (added 22/05/2023)

Registry
who.int
Start Date
April 27, 2022
End Date
November 2, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. General practice with \>4000 registered patients
  • 2\. Practice lead, or representative, confirms agreement to participate in the study after reading the practice information sheet
  • 3\. Practice lead, or representative, confirms practice support introduction of Fib\-4 testing for all patients with type 2 diabetes attending for annual review
  • 4\. Track record of \>85% of patients with type 2 diabetes attending for diabetes review
  • 5\. Practice uses EMIS computer system
  • 6\. Referral route for fibroscan based on primary care non\-invasive score agreed
  • Patient inclusion criteria:
  • 1\. Type 2 diabetes
  • 2\. Serum biochemistry sample taken alongside diabetes annual review

Exclusion Criteria

  • 1\. Inclusion criteria not met
  • 2\. Practice participating in other screening or case\-finding study related to liver fibrosis

Outcomes

Primary Outcomes

Not specified

Similar Trials